Newsroom
Our latest developments
Orca Bio’s announcements and press releases
Orca Bio Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Orca-T® to Treat Hematological Malignancies
ViewOrca Bio Appoints Key Executives Including Steve Gavel as Chief Commercial Officer
ViewOrca Bio Announces Leadership Updates
ViewOrca Bio Announces Positive Results from the Pivotal Phase 3 Study of Investigational Orca-T® Compared to Allogeneic Stem Cell Transplant for the Treatment of Hematologic Malignancies
ViewOrca Bio Presents Positive Phase 1 and 1b Data on Orca-T and Orca-Q at the 2025 Tandem Meetings of ASTCT® and CIBMTR®
ViewOrca Bio’s Orca-T® Meets Primary Endpoint in the Pivotal Precision-T Phase 3 Clinical Study for Hematologic Malignancies
ViewOrca Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference
ViewOrca Bio's fact sheets
Orca Bio Corporate Overview
View